E2F6/KDM5C promotes SF3A3 expression and bladder cancer progression through a specific hypomethylated DNA promoter

Table 1 The SF3A3 expression and clinicopathological characteristics

Characteristic	Number of patients (%)	SF3A3 expression		P value^a
Characteristic	Number of patients (%)	Low (%)	High (%)	P value^a
Patients	82	42	40
Age (years)
≤ 60^b	34	18 (52.86)	16 (47.14)	0.826
> 60	48	24 (50.55)	24 (49.45)	0.826
Gender
Male	62	30 (54.90)	32 (45.10)	0.445
Female	20	12 (45.76)	8 (54.24)	0.445
Tumor size (cm)
≤ 3.0^c	54	31 (54.72)	13 (45.28)	0.014
> 3.0	28	11 (27.27)	17 (72.73)	0.014
Tumor grade
Low	49	23 (46.39)	26 (53.61)	0.376
High	33	19 (56.25)	14 (43.75)	0.376
T classification
Ta, T1	53	31(43.81)	22 (56.19)	0.106
T2–T4	29	11(60.71)	18 (39.29)	0.106
pN status
pN−	58	32 (48.25)	26 (51.75)	0.334
pN+	24	10 (61.70)	14 (38.30)	0.334
Tumor multiplicity
Unifocal	35	14 (40.58)	21 (59.42)	0.118
Multifocal	47	28 (42.39)	19 (57.61)	0.118

Significant associations are shown in bold in the p value column (p value < 0.05)
^aChi-square test
^bMedian age
^cMedian size

ISSN: 1475-2867